Elon Musk's brain tech startup Neuralink nets $650m series E

Neuralink, a brain-computer interface company, has raised US$650 million in its series E funding round.

Notable investors include ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, and Vy Capital.

The company has made progress in developing brain-computer interfaces for individuals with severe paralysis.

The new funding is expected to accelerate Neuralink’s research and development.

It will also expand access to its devices.

🔗 Source: Neuralink

🧠 Food for thought

1️⃣ BCI funding trajectory shows market maturation beyond early skepticism

Neuralink’s journey from a $27 million funding round in 2017 to this $650 million Series E reflects the dramatic evolution in brain-computer interface market credibility 1.

Early BCI ventures faced significant funding challenges, as demonstrated when researchers Mohseni and Nudo struggled to secure investment for their neurotechnology startup before selling their “NeuraLink” trademark to Musk 2.

The market has since matured substantially, with Neuralink now valued at approximately $9 billion according to industry estimates, demonstrating increased investor confidence in commercial viability 3.

This growth mirrors broader BCI sector expansion, with the global market projected to grow from $278 million in 2025 to $734 million by 2034 at a 13.56% CAGR as applications move beyond experimental to practical implementation 4.

Government investment has also accelerated, with the U.S. Department of Defense committing $65 million to develop advanced brain-computer interfaces capable of recording from one million neurons simultaneously 5.

2️⃣ Neuralink’s path follows established pattern in medical device commercialization

Neuralink’s progression from research to human trials follows a well-established trajectory in medical device development, echoing earlier neurotechnology successes like Medtronic’s deep brain stimulators, which have been implanted in over 140,000 patients and generate approximately $500 million in annual sales 2.

The company’s focused approach on paralysis treatment as an initial application represents the typical regulatory pathway for breakthrough medical technologies, targeting specific medical conditions with clear therapeutic benefits before expanding to broader use cases 6.